Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that primarily affects women, suggesting a role of sex hormones in its pathogenesis. Hormonal therapy, particularly corticosteroids, remains a cornerstone in SLE management. Additionally, sex hormones such as estrogens and androgens have been investigated for their effects on disease activity. While estrogen is known to promote autoimmune responses, androgens may have immunosuppressive effects. This article explores the mechanisms, clinical applications, benefits, and risks of hormonal therapy in lupus. The role of corticosteroids, hormone replacement therapy (HRT), oral contraceptives, and androgens such as dehydroepiandrosterone (DHEA) is examined. A balanced approach is necessary to maximize therapeutic benefits while minimizing risks.

Systemic lupus erythematosus, hormonal therapy, corticosteroids, estrogen, androgens, DHEA, immunomodulation.

Buyon, J. P., et al. (2005). The effects of combined oral contraceptives on disease activity in systemic lupus erythematosus. New England Journal of Medicine, 353(24), 2550-2558.

Ortona, E., Pierdominici, M., & Maselli, A. (2016). Sex hormones and autoimmunity: Implications for SLE. Current Opinion in Rheumatology, 28(6), 598-603.

Petri, M., et al. (2018). Estrogen metabolism and SLE risk. Arthritis & Rheumatology, 70(7), 1061-1067.

van Vollenhoven, R. F., et al. (1999). Treatment of mild-to-moderate SLE with dehydroepiandrosterone. Arthritis & Rheumatology, 42(1), 76-84.